A study published in Diabetes Care shows that a novel rapid insulin-and-pramlintide artificial pancreas system is better in controlling glucose level than a rapid insulin-alone artificial pancreas, without increasing hypoglycemia risk, in adults with type 1 diabetes. The novel dual-hormone artificial pancreas system showed an increased time in target range and reduced mean glucose level, glucose coefficient of variance and glucose standard deviation during daytime hours, compared with a rapid insulin-alone artificial pancreas.
Study shows efficacy of insulin-and-pramlintide artificial pancreas
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.